Literature DB >> 25533327

Determining rubella immunity in pregnant Alberta women 2009-2012.

Florence Y Lai1, Douglas C Dover1, Bonita Lee2, Kevin Fonseca3, Natalia Solomon4, Sabrina S Plitt5, Joy Jaipaul6, Graham A Tipples7, Carmen L Charlton8.   

Abstract

Rubella IgG levels for 157,763 pregnant women residing in Alberta between 2009 and 2012 were analyzed. As there have been no reported cases of indigenous rubella infection in Canada since 2005, there has been a lack of naturally acquired immunity, and the current prenatal population depends almost entirely on vaccine induced immunity for protection. Rubella antibody levels are significantly lower in younger maternal cohorts with 16.8% of those born prior to universal vaccination programs (1971-1980), and 33.8% of those born after (1981-1990) having IgG levels that are not considered protective (<15 IU/mL). Analysis across pregnancies showed only 35.0% of women responded with a 4-fold increase in antibody levels following post-natal vaccination. Additionally, 41.2% of women with antibody levels <15 IU/mL had previously received 2 doses of rubella containing vaccine. These discordant interpretations generate a great deal of confusion for laboratorians and physicians alike, and result in significant patient follow-up by Public Health teams. To assess the current antibody levels in the prenatal population, latent class modeling was employed to generate a two class fit model representing women with an antibody response to rubella, and women without an antibody response. The declining level of vaccine-induced antibodies in our population is disconcerting, and a combined approach from the laboratory and Public Health may be required to provide appropriate follow up for women who are truly susceptible to rubella infection.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Prenatal screening; Rubella; Total IgG antibody levels

Mesh:

Substances:

Year:  2014        PMID: 25533327     DOI: 10.1016/j.vaccine.2014.12.022

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Response to third rubella vaccine dose.

Authors:  Lotta Siira; Hanne Nøkleby; Regine Barlinn; Øystein R Riise; Ingeborg S Aaberge; Susanne G Dudman
Journal:  Hum Vaccin Immunother       Date:  2018-06-21       Impact factor: 3.452

2.  Vaccination in secondary school students expedites rubella control and prevents congenital rubella syndrome.

Authors:  Hanqing He; Rui Yan; Xuewen Tang; Yang Zhou; Xuan Deng; Shuyun Xie
Journal:  BMC Infect Dis       Date:  2016-11-30       Impact factor: 3.090

3.  Rubella Immunity in Pregnant Native Taiwanese and Immigrants from Asian Countries.

Authors:  Yeong-Hwa Zen; Ching-Tang Shih; Wan-Ju Kung; Chien-Hung Lee; Ching-Chiang Lin
Journal:  Am J Trop Med Hyg       Date:  2016-11-28       Impact factor: 2.345

4.  How to determine protective immunity in the post-vaccine era.

Authors:  Carmen L Charlton; Florence Y Lai; Douglas C Dover
Journal:  Hum Vaccin Immunother       Date:  2016-04-02       Impact factor: 3.452

5.  Respiratory Failure and Death in Vulnerable Premature Children With Lower Respiratory Tract Illness.

Authors:  Gaston Ofman; Brad Pradarelli; Mauricio T Caballero; Alejandra Bianchi; Luciano Alva Grimaldi; Andrea Sancilio; Karina Duenas; Andrea Rodriguez; Fernando Ferrero; Adrian Ferretti; Silvina Coviello; Fausto M Ferolla; Patricio L Acosta; Eduardo Bergel; Romina Libster; Fernando P Polack
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

6.  Rubella Immune Status in Pregnant Women in a Northern Mexican City.

Authors:  Cosme Alvarado-Esquivel; Jesus Hernandez-Tinoco; Luis Francisco Sanchez-Anguiano; Agar Ramos-Nevarez; Sandra Margarita Cerrillo-Soto; Jose Manuel Salas-Pacheco; Ada Agustina Sandoval-Carrillo; Lucio Martinez-Ramirez; Elizabeth Irasema Antuna-Salcido; Carlos Alberto Guido-Arreola
Journal:  J Clin Med Res       Date:  2016-07-30

7.  Recent trends in seroprevalence of rubella in Korean women of childbearing age: a cross-sectional study.

Authors:  Rihwa Choi; Yejin Oh; Youngju Oh; Sung Ho Kim; Sang Gon Lee; Eun Hee Lee
Journal:  BMJ Open       Date:  2020-01-02       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.